Pure Biologics’ portfolio focuses primarily on new immuno-oncology biological drugs and non-systemic therapies for patients suffering from autoimmune, neurological and other rare diseases. In 2018, we launched our first development project focused on an innovative biologic drug, with further new ideas introduced in the years that followed. Since then, we remain committed to building a balanced portfolio of active biological molecules with therapeutic potential. By leveraging our technology platforms, we independently conduct all phases of drug discovery and development projects, as well as diagnostic and therapeutic projects, steering them all to a point of entry into preclinical studies. Pure Biologics also participates in collaborative projects with Polish and international scientific research units, helping to build and sustain a scientific partnership network, and to ensure our teams’ standing as leaders in the biopharmaceutical sector.
Pure Biologics is focused on “smart drug development” (the “Smart IO” approach). We are developing drug candidates whose comprehensive mechanism of action is likely to provide a competitive advantage over solutions developed by other companies targeting the same antigens that have already demonstrated therapeutic potential and safety in clinical trials. Our portfolio includes projects with significant advantages over competing solutions, with the potential to be first-in-class.
As part of our non-systemic therapy segment, biomolecular filters based on active aptamers are being developed. This technology, utilizing available hospital infrastructure and apheresis solutions, gives us the ability to operate in any area where specific capture of a pathogen from the blood is required.